Undisclosed Program (DR)
Diabetic Retinopathy
Pre-clinical / ClinicalIn pipeline; uses ADS Platform
Key Facts
Indication
Diabetic Retinopathy
Phase
Pre-clinical / Clinical
Status
In pipeline; uses ADS Platform
Company
About Cloudbreak Pharmaceutical
Founded in 2015 and headquartered in Irvine, California, Cloudbreak Pharmaceutical is a global biotech focused on transforming ophthalmic care through innovative drug development. The company has advanced its lead asset, CBT-001, into Phase 3 trials following a successful End-of-Phase 2 meeting with the FDA, positioning it as a potential first therapeutic for pterygium. Cloudbreak's strategy combines in-house R&D expertise with strategic regional partnerships, including agreements with Santen and Grand Pharma, to develop and commercialize its pipeline across major markets.
View full company profileTherapeutic Areas
Other Diabetic Retinopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| NOX4 Inhibitor (GLX7013114) | Glucox Biotech | Preclinical |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| jCell (RPCs) | jCyte | Preclinical |
| LumineticsCore | Digital Diagnostics | Approved |
| Diabetic Retinopathy Program | Lxbio Pharmaceuticals | Pre-clinical |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical |
| NBP-14 and derivatives | Neuro Bio | Research |
| Vasculogenic Cell Therapy | Vascugen | Pre-clinical |
| Danegaptide | Breye Therapeutics | Phase 2 |
| OcuRetina | Oculotix | Phase 2 |
| YH14618 | Yuhan | Phase 2 |